Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

Autor: Pagano, Livio, Salmanton-Garcia, J., Marchesi, F., Blennow, O., Gomes da Silva, M., Glenthoj, A., van Doesum, J., Bilgin, Y. M., Lopez-Garcia, A., Itri, F., Nunes Rodrigues, R., Weinbergerova, B., Farina, F., Dragonetti, Giulia, Berg Venemyr, C., van Praet, J., Jaksic, O., Valkovic, T., Falces-Romero, I., Martin-Perez, S., Jimenez, M., Davila-Valls, J., Schonlein, M., Ammatuna, E., Meers, S., Delia, M., Stojanoski, Z., Nordlander, A., Lahmer, T., Imre Pinczes, L., Buquicchio, C., Piukovics, K., Ormazabal-Velez, I., Fracchiolla, N., Samarkos, M., Mendez, G. -A., Hernandez-Rivas, J. -A., Espigado, I., Cernan, M., Petzer, V., Lamure, S., di Blasi, R., Marques de Almedia, J., Dargenio, M., Biernat, M. M., Sciume, M., de Ramon, C., de Jonge, N., Batinic, J., Aujayeb, A., Marchetti, M., Fouquet, G., Fernandez, N., Zambrotta, G., Sacchi, M. V., Guidetti, A., Demirkan, F., Prezioso, L., Racil, Z., Nucci, M., Mladenovic, M., Lievin, R., Hanakova, M., Grafe, S., Sili, U., Machado, M., Cattaneo, C., Adzic-Vukicevic, T., Verga, L., Labrador, J., Rahimli, L., Bonanni, Matteo, Passamonti, F., Pagliuca, A., Corradini, P., Hoenigl, M., Koehler, P., Busca, A., Cornely, O. A., Serrano, L., Ribera-Santa Susana, J. -M., Meletiadis, J., Tsirigotis, P., Coppola, N., Mikulska, M., Erben, N., Besson, C., Merelli, M., Gonzalez-Lopez, T. -J., Loureiro-Amigo, J., Garcia-Vidal, C., Kort, E. D., Cuccaro, A., Zompi, S., Reizine, F., Finizio, O., Dulery, R., Calbacho, M., Abu-Zeinah, G., Malak, S., Zdziarski, P., Varrichio, G., Tragiannidis, A., Plantefeve, G., Duarte, R., Danion, F., Tisi, M. C., Sakellari, I., Karthaus, M., Groh, A., Fung, M., Emarah, Z., Coronel-Ayala, O. -F., Ann Chai, L. Y., Brehon, M., Bonuomo, V., Wolf, D., Wittig, J., Vehreschild, M., Papa, M. V., Neuhann, J., Jimenez-Lorenzo, M. -J., Grothe, J., Gavriilaki, E., Garcia-Sanz, R., Garcia-Pouton, N., El-Ashwah, S. S., Eggerer, M., Cordoba, R., Colak, G. M., Arellano, E.

Publikováno v: Blood, 140(26), 2773-2787. American Society of Hematology
Blood
Volume 140
Issue 26
Blood, vol 140, iss 26
EPICOVIDEHA Survey members 2022, ' Breakthrough COVID-19 in vaccinated patients with hematologic malignancies : results from the EPICOVIDEHA survey ', Blood, vol. 140, no. 26, pp. 2773-2787 . https://doi.org/10.1182/blood.2022017257
Blood, 140(26). AMER SOC HEMATOLOGY
Pagano, L, Salmanton-garcía, J, Marchesi, F, Blennow, O, Gomes Da Silva, M, Glenthøj, A, Van Doesum, J A, Bilgin, Y M, Lopez-garcia, A, Itri, F, Nunes Rodrigues, R, Weinbergerová, B, Farina, F, Dragonetti, G, Berg Venemyr, C, Van Praet, J, Jaksic, O, Valkovic, T, Falces-romero, I, Martin-perez, S, Jiménez, M, Davila-valls, J, Schonlein, M, Ammatuna, E, Meers, S, Delia, M, Stojanoski, Z, Nordlander, A, Lahmer, T, Pinczés, L I, Buquicchio, C, Piukovics, K, Ormazabal-velez, I, Fracchiolla, N S, Samarkos, M, Mendez, G, Hernández-rivas, J, Espigado, I, Cernan, M, Petzer, V, Lamure, S, Di Blasi, R, Marques De Almeida, J, Dargenio, M, Biernat, M M, Sciumè, M, De Ramón, C, De Jonge, N A, Batinic, J, Aujayeb, A, Marchetti, M, Fouquet, G, Fernández Escalada, N, Zambrotta, G P M, Sacchi, M V, Guidetti, A, Demirken, F, Prezioso, L, Racil, Z, Nucci, M, Mladenovic, M, Lievin, R, Hanakova, M, Grafe, S K, Sili, U, Machado, M, Cattaneo, C, Adzic-vukicevic, T, Verga, L, Labrador, J, Rahimli, L, Bonanni, M, Passamonti, F, Pagliuca, A, Corradini, P, Hoenigl, M, Koehler, P, Busca, A & Cornely, O A 2022, ' Breakthrough COVID-19 in vaccinated patients with hematologic malignancies : results from EPICOVIDEHA survey ', Blood, pp. 2773–2787 . https://doi.org/10.1182/blood.2022017257

Limited data are available on breakthrough COVID-19 in patients with hematologic malignancy (HM) after anti–severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Adult patients with HM, ≥1 dose of anti-SARS-CoV-2 vaccine, and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46d068f242283040ec3d5be079ebd89c
https://research.vumc.nl/en/publications/c62a76e2-fca2-45ed-a697-f1017ce3b6ec

Breakthrough COVID-19 in vaccinated patients with hematologic malignancies: results from the EPICOVIDEHA survey

Autor: Pagano L, Salmanton-García J, Marchesi F, Blennow O, Gomes da Silva M, Glenthøj A, van Doesum J, Bilgin YM, López-García A, Itri F, Nunes Rodrigues R, Weinbergerová B, Farina F, Dragonetti G, Berg Venemyr C, van Praet J, Jaksic O, Valković T, Falces-Romero I, Martín-Pérez S, Jiménez M, Dávila-Valls J, Schönlein M, Ammatuna E, Meers S, Delia M, Stojanoski Z, Nordlander A, Lahmer T, Imre Pinczés L, Buquicchio C, Piukovics K, Ormazabal-Vélez I, Fracchiolla N, Samarkos M, Méndez GA, Hernández-Rivas JÁ, Espigado I, Cernan M, Petzer V, Lamure S, di Blasi R, Marques de Almedia J, Dargenio M, Biernat MM, Sciumè M, de Ramón C, de Jonge N, Batinić J, Aujayeb A, Marchetti M, Fouquet G, Fernández N, Zambrotta G, Sacchi MV, Guidetti A, Demirkan F, Prezioso L, Ráčil Z, Nucci M, Mladenović M, Liévin R, Hanáková M, Gräfe S, Sili U, Machado M, Cattaneo C, Adžić- Vukičević T, Verga L, Labrador J, Rahimli L, Bonanni M, Passamonti F, Pagliuca A, Corradini P, Hoenigl M, Koehler P, Busca A, Cornely OA.

Limited data are available on breakthrough COVID- 19 in patients with hematologic malignancy (HM) after anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Adult patients with HM, ≥1 dose of anti-SARS-CoV-2 vaccine, and b

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=57a035e5b1ae::17630ac5513ee7c883f0a157437b0e16
https://www.bib.irb.hr/1253907

Monocytes are activated in patients with myelodysplastic syndromes and can contribute to bone marrow failure through CD40–CD40L interactions with T helper cells.

Autor: Meers, S.¹ stef.meers@med.kuleuven.be, Kasran, A.², Boon, L.³, Lemmens, J.⁴, Ravoet, C.⁵, Boogaerts, M.⁶, Verhoef, G.⁶, Verfaillie, C.¹, Delforge, M.¹

Publikováno v: Leukemia (08876924). Dec2007, Vol. 21 Issue 12, p2411-2419. 9p. 2 Charts, 5 Graphs.

Plerixafor in poor stem cell mobilizers : the belgian compassionate use program

Autor: Selleslag, D., Dierickx, D., Breems, D.A., Huynh, P., Van de Velde, Ann, Meers, S., Brouwer, E., Mertens, A.

Publikováno v: Acta clinica Belgica

Introduction: Currently available stem cell mobilizing regimens (G-CSF +/- chemotherapy) show high failure rates, especially in heavily pretreated patients. Plerixafor, a new stem cell mobilizing agent blocking the CXCR4-SDF-1 interaction, offers a n

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2097::1ac3ee32bb33490014e20239d8cdede7
https://hdl.handle.net/10067/1130570151162165141

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.